PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

Authors :: Larry D. Anderson
M.A. Dimopoulos
A. Bensmaine
P. Moreau
T. Vi Nguyen
Pieter Sonneveld
Matthew W Jenner
Katja Weisel
Darrell White
J. Dürig
M. Salomo
P. G. Richardson
J. San Miguel
M. Pavic
X Yu
Alessandro Corso
Teresa Peluso
M. Zaki
Monika Engelhardt
Source :: HemaSphere. 3:250-251
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
medicine.medical_specialty
Bortezomib
business.industry
Line of therapy
Subgroup analysis
Hematology
medicine.disease
Pomalidomide
Internal medicine
medicine
In patient
business
Multiple myeloma
Dexamethasone
Lenalidomide
medicine.drug

Tools